Swiss multinational healthcare company, Roche, has terminated its worldwide license and collaboration agreement with Repare Therapeutics despite the company earning a $40 million milestone payment from Roche.
Clinical-stage precision oncology company, Repare Therapeutics Inc., has received a $40 million milestone payment from Roche after dosing the first patient in a clinical trial.
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
The company unveils the creation of the Institute of Human Biology, which will provide efficacy studies of drug candidates using miniature ‘living replicas’ of human tissues and organs.
UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
A Touch, the Black Breast Cancer Alliance leader discusses how a grant from Genentech is helping the organization break down barriers in care and research.
Through its Health Equity and Diversity in STEM Innovation Fund, the biotech is looking to increase equity in care and diversify the scientific workforce.
Leaders from some of the industry’s most notable companies are working together to streamline and automate IDMP workflow and come up with various standards.
The companies plan to work on developing personalized care solutions via digital pathology to come up with treatment options for patients with solid tumors.
The agency’s effort to fight the deadly disease now includes taps the pharma company’s testing tools to help speed up diagnosis and grow treatment access.
The Orchestrated Customer Engagement Technology reportedly has been adopted by 140 life sciences companies (including top-10 pharma firms) in nearly 90 countries.
The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.
Organizations or individuals desiring change is often the reason for retirements, but the timing is often crucial and so it proved for two major institutions in the UK.
Roche agrees for Sanofi to be responsible for the OTC marketing and distribution of Tamiflu in the US market, as it works on approval for its Xofluza competitor product.
Janssen aims to expand the label of delivery in the US and EU for its product, Darzalex, to include subcutaneous delivery through the use of Halozyme’s technology.
Pharma and regulators are using machine learning to accelerate various pharmacovigilance activities – as the number of adverse event reports increases 10-12% each year, says Eli Lilly advisor.
Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.
The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.
Roche has launched its new cobas pro integrated solutions to reduce manual operations in the lab – as well as new enterprise software for digital pathology.
“Small molecule products should be packaged at the location where they are produced,” says Roche, which is laying-off 235 jobs at a packaging plant in Switzerland.
To benefit from breakthrough therapy designation (BTD) pharma companies must be willing “bet on the right data” according to Roche, which says this could be a challenge for smaller firms.
Drug raw materials suppliers have not recognised their potential value to biopharmaceutical customers according to Roche which has called for a transformation in the vendor relationship.
Manufacturing powerhouse Roche is doubling down on its small molecule manufacturing with investments of $134.6m in two facilities in Basel, Switzerland.
Bidders for DNA-sequencing equipment maker Life Technologies may not have to pay too much more than its current market value of $64 per share, or about $11B, according to an analyst.
Swiss drug major Roche has called in biomarker testing lab Rules-Based Medicine (RBM) to help give its candidate schizophrenia drugs a commercial edge.
Medidata has followed up its successful IPO by inking a deal with Roche, which is reported to be pulling out of PhRMA and the ABPI, to provide the Swiss pharma with an enterprise-wide electronic EDC system.
A new $60m (€43m) manufacturing suite is operational at the South Carolina, US plant where Roche makes APIs for some of its leading products, including for its anti-flu drug Tamiflu (oseltamivir).
Just weeks after expanding its relationship with AstraZeneca, Chinese CRO BioDuro has been asked by Swiss drug major Roche to help with its discovery phase R&D programme.
A filing with the SEC says that Roche is not prepared to continue in a relationship with Genentech in which it owns a majority of the biotech’s equity but has limited involvement in its governance.
